Rene Hersperger
Novartis Institutes for BioMedical Research and Novartis Pharma Development
CH-4002 Basle
Switzerland
Name/email consistency: high
- A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. Hersperger, R., Buchheit, K.H., Cammisuli, S., Enz, A., Lohse, O., Ponelle, M., Schuler, W., Schweitzer, A., Walker, C., Zehender, H., Zenke, G., Zimmerlin, A.G., Zollinger, M., Mazzoni, L., Fozard, J.R. J. Med. Chem. (2004)
- Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. Hersperger, R., Dawson, J., Mueller, T. Bioorg. Med. Chem. Lett. (2002)
- Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. Hersperger, R., Bray-French, K., Mazzoni, L., Müller, T. J. Med. Chem. (2000)
- Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin. Hersperger, R., Schuler, W., Zenke, G. Bioorg. Med. Chem. Lett. (1999)









